Short answer
Vanda Pharmaceuticals Inc. (VNDA) filed an 8-K current report with the SEC on May 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q1 2026 results covered quarter ended March 31, 2026.
Vanda Pharmaceuticals Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results covered quarter ended March 31, 2026
- Press release furnished as Exhibit 99.1; financial figures require review of the exhibit
- Earnings call includes updates on commercial products, pipeline development, regulatory timelines, and commercial potential
- Forward-looking statements carry execution risk around U.S. business strength and clinical or regulatory approvals
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vanda Pharmaceuticals Inc. 8-K filings
Get the next VNDA 8-K as it lands
Follow VNDA for push alerts, or ask the research agent what this filing means.